Understanding how mycobacteria build their cell walls and resist antibiotics
Control of cell wall synthesis and antibiotic tolerance in mycobacteria
This study is looking at how the tuberculosis bacteria builds its protective wall and learns to survive against antibiotics, with the goal of finding better treatments for people with tuberculosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project ID | NIH-10839329 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which Mycobacterium tuberculosis, the bacteria responsible for tuberculosis, regulates its cell wall synthesis and develops tolerance to antibiotics. The team aims to create a molecular model that explains how environmental signals influence the activity of key regulators involved in cell wall metabolism. By studying specific proteins and their phosphorylation, the research seeks to uncover how these processes affect the bacteria's growth and survival under stress, particularly in the presence of antibiotics. This knowledge could lead to the development of more effective treatments for tuberculosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those who have shown resistance to standard antibiotic treatments.
Not a fit: Patients who do not have tuberculosis or those with non-infectious diseases are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the creation of new antibiotics that are more effective against tuberculosis.
How similar studies have performed: Previous research has shown promise in understanding bacterial resistance mechanisms, indicating that this approach could yield valuable insights.
Where this research is happening
Arlington, United States
- University of Texas Arlington — Arlington, United States (Active)
Researchers
- Principal investigator: Boutte, Cara Cheney — University of Texas Arlington
- Study coordinator: Boutte, Cara Cheney
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.